New York, NY - (ACCESSWIRE) - 09/24/2013 - Equity Profile Report initiates its NASDAQ Active Stock Watch List adding First Solar, Inc. (NASDAQ:FSLR), Linn Energy, LLC (NASDAQ:LINE), Geron Corporation (NASDAQ:GERN), and Celldex Therapeutics, Inc. (NASDAQ:CLDX).

First Solar, Inc. (NASDAQ:FSLR) a company that provides solar energy solutions closed down in its previous session (-0.62%) on 2,914,523 shares traded. First Solar, Inc. (NASDAQ:FSLR) is currently down (-35.07%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about First Solar, Inc. (NASDAQ:FSLR)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=FSLR&SubId=AW

Linn Energy, LLC (NASDAQ:LINE) an independent oil and natural gas company that engages in the acquisition and development of oil and natural gas properties closed down in its previous session (-0.50%) on 1,567,012 shares traded. Linn Energy, LLC (NASDAQ:LINE) is currently down (-40.94%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Linn Energy, LLC (NASDAQ:LINE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=LINE&SubId=AW

Geron Corporation (NASDAQ:GERN) a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies closed up in its previous session (+28.14%) on 6,167,983 shares traded. Geron Corporation (NASDAQ:GERN) is currently up (+249.45%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Geron Corporation (NASDAQ:GERN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=GERN&SubId=AW

Celldex Therapeutics, Inc. (NASDAQ:CLDX) a biopharmaceutical company that focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States closed up in its previous session (+12.85%) on 6,561,668 shares traded after Leerink Swann raised its price target on the stock to $45 from $28. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is currently up (+555.38%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=CLDX&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com